Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2350 (LINC02350)
- Target
- LINC02350
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01
Overview
LINC02350 (Long intergenic non-protein coding RNA 2350) is a long non-coding RNA gene transcribed from an intergenic region in the human genome. It does not encode a protein but instead produces an RNA molecule that may participate in regulatory functions such as chromatin remodeling, transcriptional regulation, and maintenance of nuclear architecture. Like other lincRNAs, it is hypothesized to fine-tune gene expression with tissue specificity. LINC02350 has been identified by bioinformatic methods as a candidate biomarker for the diagnosis of lung cancer due to its differential expression in cancer versus normal tissue, but its clinical utility and precise biological roles remain to be experimentally validated.
- Other names
- LINC02350
02
Mechanism of action
Not applicable. LINC02350 does not have a defined mechanism of action for drug interaction. The general mechanisms for lincRNAs include regulation of transcription and chromatin state.
03
Biological functions
Chromatin remodelingGene expression regulationTranscriptional regulationPotential scaffold functions for nuclear architecture
04
Disease associations
Potential as a biomarker in cancer (especially lung cancer), based on bioinformatics analyses identifying lincRNAs (including LINC02350) as differentially expressed and useful for predicting lung cancer diagnosis.Specific disease roles for LINC02350 remain unclear due to limited experimental validation; however, the lincRNA family is broadly involved in cancer and immune response regulation.
05
Safety considerations
None directly reported.Therapeutic targeting of lincRNAs is uncommonly pursued, and the clinical impact of modulating LINC02350 activity is unknown.
06
Biomarkers
LINC02350 has been proposed as a diagnostic biomarker candidate in lung cancer, as part of a panel of lncRNAs that showed high sensitivity and specificity for discriminating tumor from normal samples in bioinformatic analyses.
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2350 (LINC02350).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2350 (LINC02350).